Browsing Tag
FDA IND
3 posts
How SC-dosed NK cell engagers like GTB-5550 could disrupt cancer care delivery models
GT Biopharma’s GTB-5550 receives FDA clearance with subcutaneous delivery. See how this trial could shift NK immunotherapy into outpatient cancer care.
Is Imagion Biosystems (ASX: IBX) on the cusp of a breakout? FDA optimism lifts Phase 2 hopes, but market sentiment remains cautious
Imagion Biosystems is progressing toward a key FDA filing and Phase 2 trial for its HER2 imaging agent. Find out why IBX could be at a turning point.
FDA clears Mabwell’s next-gen ADC 7MW4911: What’s at stake in the global GI oncology race?
Mabwell secures FDA IND for CDH17-targeting ADC 7MW4911, marking a major step in GI cancer therapy. Find out how this could reshape advanced oncology care.